TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06715839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-H2D3
Description: Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[68Ga\]Ga-DOTA-H2D3). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-DOTA-H2D3 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-RB14
Description: Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[18F\]F-RESCA-RB14). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RB14 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-T4
Description: Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[68Ga\]Ga-NOTA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-T4
Description: Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[18F\]F-RESCA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-G5
Description: Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[68Ga\]Ga-NOTA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-G5 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-G5
Description: Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[18F\]F-RESCA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-G5 injection.
Study: NCT04938388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Pill
Description: All participants will start at a 3 mg dose of OS or matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose (or Placebo) will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose (or Placebo) will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS (or Placebo) will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fresh organic vegetables
Description: Prescriptions of organic vegetables

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresh organic vegetables
Description: Prescriptions of organic vegetables
Study: NCT05473598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stand Down app
Description: Patients in this condition will receive Usual Care (UC) and be provided a unique code and password to access Stand Down. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support. App usage will be tracked by the research team for the duration of the study (32 weeks).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stand Down app
Description: Patients in this condition will receive Usual Care (UC) and be provided a unique code and password to access Stand Down. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support. App usage will be tracked by the research team for the duration of the study (32 weeks).
Study: NCT06109220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stromal vascular fraction,SVF
Description: SVF was injected into the knee cavity
Study: NCT04875624

Intervention type: DIAGNOSTIC_TEST
Intervention: Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4)
Description: Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) will be administered by one of the 2 blinded examiners who are unaware of neonatal glycemia status. Bayley-4 examines Cognitive, Language, Motor, Social-Emotional and Adaptive Behavior domains of development and may require up to 120 minutes to complete.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4)
Description: Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) will be administered by one of the 2 blinded examiners who are unaware of neonatal glycemia status. Bayley-4 examines Cognitive, Language, Motor, Social-Emotional and Adaptive Behavior domains of development and may require up to 120 minutes to complete.
Study: NCT05486052

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of reliability, repeatability and validity of devices among healthy subjects
Description: Evaluation of reliability, reproducibility and validity of devices among healthy subjects Prior to the study among individuals with neurological disorders, an evaluation of the reliability, repeatability and credibility of the devices to be included in the biofeedback rehabilitation and optical oximetry measurements will be carried out.~The evaluation of the devices will be carried out by two independent researchers twice

Intervention type: OTHER
Group type: OTHER
Intervention: Biofeedback method and Health-resort based rehabilitation Health-resort based treatments supplemented with biofeedback training
Description: The rehabilitation programme will run for 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massages, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy.~Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, peat wraps, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Health-resort based rehabilitation Control group - health-resort based treatments, without biofeedback training.
Description: Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: Health-resort based rehabilitation Control group - health-resort based treatments, without biofeedback training.
Description: Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy
Study: NCT05473598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Supported Stand Down
Description: Patients assigned to this condition will receive UC and access to Stand Down, plus four phone sessions from a Peer over 8 weeks. Sessions will be bi-weekly, approx. 15-30 minutes in length, and focus on enhancing patients' engagement with the app.
Study: NCT05877469

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mat pilates Training
Description: In this group 22 patients will perform mat pilates training. Patients will be asked to stay comfortable while performing mat pilates exercies that involve different types of movements of whole body like leg lifts, toe taps, Single leg stretch, one leg circle, side bend preparation, side kicks, side leg lifts, roll down and crisscross to improve the core strength. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Training
Description: In this group 22 patients will perform functional training. Patients will be instructed to perform their daily living movements like squatting, reaching, or even carrying a heavy object. These exercises typically use the whole body and emphasize core strength and stability. Functional training typically uses weight-bearing activities that work the core muscles in the torso. the functional movements include involve glute bridge, squats, pushups, lateral lunge, step up to shoulder press, goblet and squats. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
Study: NCT06035588

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily whitening
Description: Daily application of a 16% carbamide peroxide bleaching gel in volunteers without sensitivity.
Study: NCT06715839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-WWH347
Description: Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[68Ga\]Ga-NOTA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-WWH347 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-WWH347
Description: Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[18F\]F-RESCA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-WWH347 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-RND20
Description: Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[68Ga\]Ga-NOTA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RND20 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-RND20
Description: Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[18F\]F-RESCA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RND20 injection.
Study: NCT06717113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG
Description: Prior to the examination, patients will be required to fast for at least 6 hours. 18F-FDG (0.05-0.1 mCi/kg) will be intravenously injected, and one hour after the injection, head and torso imaging will be performed using a Shanghai United Imaging uMI 780 PET/CT scanner, covering the region from the top of the head to the upper third of the thigh. The patient will lie supine and breathe calmly during the procedure. After image acquisition, the data will be reconstructed using the OSEM method to generate coronal, sagittal, transverse, and PET/CT fusion images.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BC1
Description: The prepared and quality-controlled 68Ga-BC1 (0.05-0.1 mCi/kg) will be intravenously injected into the patient. Two hours after the injection, whole-body imaging will be performed using a Shanghai United Imaging uMI 780 PET/CT scanner, covering the region from the top of the head to the mid-thigh. If any indeterminate lesions are found during the routine imaging, delayed imaging will be performed for further differentiation. The patient will lie supine and breathe calmly during the procedure. After image acquisition, the data will be reconstructed using the OSEM method to generate coronal, sagittal, transverse, and PET/CT fusion images.
Study: NCT06715046

Intervention type: DIAGNOSTIC_TEST
Intervention: Sample collation for cfDNA methylation analysis
Description: Sample collation for cfDNA methylation analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Sample collation for cfDNA methylation analysis
Description: Sample collation for cfDNA methylation analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Sample collation for cfDNA methylation analysis
Description: Sample collation for cfDNA methylation analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Sample collation for cfDNA methylation analysis
Description: Sample collation for cfDNA methylation analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Sample collection for EV phenotype analysis
Description: Analysis of the EV phenotype to evaluate their potential value as markers for GVHD, relapse and engraftment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sample collection for EV phenotype analysis
Description: Analysis of the EV phenotype to evaluate their potential value as markers for GVHD, relapse and engraftment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sample collection for EV phenotype analysis
Description: Analysis of the EV phenotype to evaluate their potential value as markers for GVHD, relapse and engraftment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sample collection for EV phenotype analysis
Description: Analysis of the EV phenotype to evaluate their potential value as markers for GVHD, relapse and engraftment.
Study: NCT06035588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate whitening
Description: Volunteers will apply the whitening gel at 16% carbamide peroxide, alternating a rest day with an application day. Patients should not be sensitive before starting the study.
Study: NCT04846387

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: A T1-weighted Anatomical Image, Diffusion Weighted Image, and functional MRI (fMRI) of empty bladder image will be obtained.~Additionally, fMRI image during full bladder state and voiding/holding tasks will be obtained.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: A T1-weighted Anatomical Image, Diffusion Weighted Image, and functional MRI (fMRI) of empty bladder image will be obtained.~Additionally, fMRI image during full bladder state and voiding/holding tasks will be obtained.
Study: NCT05399030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-332
Description: ICP-332 will be administered as tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as tablet
Study: NCT05972044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg
Description: Solriamfetol tablets, taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Description: Solriamfetol tablets, taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, taken once daily
Study: NCT05275452

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05651516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PI-2620 PET/CT
Description: PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.
Study: NCT05278676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotinurad
Description: Dotinurad oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotinurad
Description: Dotinurad oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotinurad
Description: Dotinurad oral tablet.
Study: NCT05560178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEXUAL HEALTH EDUCATION
Description: Women in the intervention group will be given sexual health education once a week for 4 weeks
Study: NCT05942729

Intervention type: OTHER
Intervention: Determine the etiology of hypokinetic and hypertrophic heart disease on transthoracic echocardiography data alone
Description: The origin of the pathology will have been previously diagnosed for each patient thanks to complementary examinations performed as part of routine care (e.g. cardiac CT, cardiac MRI, coronary angiography, thorough biology, nuclear medicine). This information will be used (i) to guide the learning of the AI method developed during the project from a sub-population (80% of the collected database will be used to train the algorithms); (ii) to serve as an evaluation criterion from a test sub-population (remaining 20% of the collected database)

Intervention type: OTHER
Intervention: Determine the etiology of hypokinetic and hypertrophic heart disease on transthoracic echocardiography data alone
Description: The origin of the pathology will have been previously diagnosed for each patient thanks to complementary examinations performed as part of routine care (e.g. cardiac CT, cardiac MRI, coronary angiography, thorough biology, nuclear medicine). This information will be used (i) to guide the learning of the AI method developed during the project from a sub-population (80% of the collected database will be used to train the algorithms); (ii) to serve as an evaluation criterion from a test sub-population (remaining 20% of the collected database)
Study: NCT06261242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)
Description: The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
Study: NCT05875129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAVA prototype
Description: Cognitive behavioral therapy for insomnia
Study: NCT05351333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Sugar pill, with an essential-oil smell and of blue color used for conditioning.
Study: NCT05901896

Intervention type: OTHER
Intervention: there are no intervention
Description: no intervention

Intervention type: OTHER
Intervention: there are no intervention
Description: no intervention
Study: NCT06077110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-OMICs-flow services
Description: The Service Intervention is the P-OMICs-flow clinic being delivered at The Prince of Wales Hospital. This clinic provides a streamlined, multidisciplinary model to seamlessly integrate research-led precision medicine into the routine oncology setting.
Study: NCT05514145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nance/Transpalatal arch space maintainer
Description: A combined design of both Nance and Transpalatal arch space maintainers as a space maintainer for the maxillary arch in mixed dentition

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nance space maintainer
Description: Conventional space maintainer for the maxillary arch used in mixed dentition
Study: NCT06016140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication plan
Description: Involved participants will jointly agreed on continued medication treatment (treatment aim, planned monitring and evaluation and responsibility, and the physician will document the plan in the electronic health record
Study: NCT06066957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir 480 MG [Prevymis]
Description: Letermovir for CMV prophylaxis in thoracic organ transplant recipients.~Letermovir will be administered by oral administration, as per study protocol. The intended duration of therapy will be up to 365 days, depending on organ transplanted and donor and recipient CMV status. However, treatment may discontinued as discussed in Section 7.~Letermovir is dosed at 480mg daily for patients with CrCl \>10. Dose adjustment, as per package insert, is recommended in setting of co-administration of cyclosporine, with dose reduction of letermovir to 240mg daily. Missed doses of letermovir will not be made up.
Study: NCT06144242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on RTD metric
Description: Clinicians in the experimental arm will receive feedback on the RTD metric while clinicians in the No intervention arm will not.
Study: NCT06086756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure intervention plus positive mood induction
Description: Positive mood induction followed by a brief VR exposure session for public speaking anxiety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure intervention plus negative mood induction
Description: Negative mood induction followed by a brief VR exposure session for public speaking anxiety.
Study: NCT05473598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Supported Stand Down
Description: Patients assigned to this condition will receive UC and access to Stand Down, plus four phone sessions from a Peer over 8 weeks. Sessions will be bi-weekly, approx. 15-30 minutes in length, and focus on enhancing patients' engagement with the app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer-Supported Stand Down
Description: Patients assigned to this condition will receive UC and access to Stand Down, plus four phone sessions from a Peer over 8 weeks. Sessions will be bi-weekly, approx. 15-30 minutes in length, and focus on enhancing patients' engagement with the app.
Study: NCT05570799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality and Kahoot game learning
Description: * An augmented reality (AR) mobile application with image based will be used by the participants in the experimental group.~* Also, students will participate in Kahoot game. Students will participate in the game using their own devices by going to https://kahoot on their phones and entering their password and password.